Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.

Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG (2014)

In: Clinical Pharmacology and Therapeutics, 96(2), 156-7. doi:10.1038/clpt.2014.67

Research article (journal) | Peer reviewed | Published

Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E (2010)

In: American Journal of Pathology, 176(3), 1169-1180. doi:10.2353/ajpath.2010.090610

Research article (journal) | Peer reviewed | Published

Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.

Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A (2008)

In: Ear and Hearing, 29(6), 830-837.

Research article (journal) | Peer reviewed | Published

Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

In: , -.

| Peer reviewed

[Cisplatin-induced hearing loss in children in relation to eye color]

In: , -.

| Peer reviewed

Publications

Operated by

Top-Links

Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG (2014) In: Clinical Pharmacology and Therapeutics, 96(2), 156-7. doi:10.1038/clpt.2014.67 Research article (journal) \| Peer reviewed \| Published
Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM (2012) In: International journal of pediatric otorhinolaryngology, 76(1), 131-136. doi:10.1016/j.ijporl.2011.10.020 Research article (journal) \| Peer reviewed \| Published
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E (2010) In: American Journal of Pathology, 176(3), 1169-1180. doi:10.2353/ajpath.2010.090610 Research article (journal) \| Peer reviewed \| Published
Organic cation transporters as potential target molecules for protective interventions against cisplatin-induced nephrotoxicity Ciarimboli G, Deuster D, Knief A, Humberg J, Pavenstadt H, Zehnhoff-Dinnesen AA, Schlatter E (2009) In: Pediatric Nephrology, 24(4). Research article (journal) \| Published
Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A (2008) In: Ear and Hearing, 29(6), 830-837. Research article (journal) \| Peer reviewed \| Published
Cisplatin Ototoxicity - From dose to molecular biology In: .
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. In: , -. \| Peer reviewed
The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy In: , . \| Peer reviewed
[Cisplatin-induced hearing loss in children in relation to eye color] In: , -. \| Peer reviewed
Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters In: , -. \| Peer reviewed